A detailed history of Barclays PLC transactions in Biogen Inc. stock. As of the latest transaction made, Barclays PLC holds 22,700 shares of BIIB stock, worth $3.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,700
Previous 921,256 97.54%
Holding current value
$3.39 Million
Previous $179 Million 97.54%
% of portfolio
0.0%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$189.07 - $236.8 $89.5 Million - $112 Million
473,603 Added 105.8%
921,256 $179 Million
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $17.7 Million - $22 Million
-92,912 Reduced 17.19%
447,653 $104 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $1.76 Million - $2.22 Million
8,305 Added 1.56%
540,565 $117 Million
Q4 2023

Feb 15, 2024

BUY
$222.59 - $267.94 $30.4 Million - $36.6 Million
136,584 Added 34.52%
532,260 $138 Million
Q3 2023

Nov 07, 2023

SELL
$253.3 - $285.89 $48.7 Million - $54.9 Million
-192,085 Reduced 32.68%
395,676 $102 Million
Q2 2023

Aug 03, 2023

BUY
$275.25 - $318.06 $35.8 Million - $41.3 Million
129,918 Added 28.38%
587,761 $167 Million
Q1 2023

May 04, 2023

SELL
$256.56 - $292.34 $42.3 Million - $48.2 Million
-164,885 Reduced 26.48%
457,843 $127 Million
Q4 2022

Feb 13, 2023

BUY
$252.44 - $306.72 $72.4 Million - $88 Million
286,871 Added 85.41%
622,728 $172 Million
Q3 2022

Nov 03, 2022

BUY
$194.69 - $268.46 $4.54 Million - $6.27 Million
23,342 Added 7.47%
335,857 $89.7 Million
Q2 2022

Aug 12, 2022

SELL
$187.54 - $223.02 $12.5 Million - $14.9 Million
-66,866 Reduced 17.63%
312,515 $63.7 Million
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $84.7 Million - $107 Million
-437,190 Reduced 53.54%
379,381 $79.9 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $96.7 Million - $124 Million
431,657 Added 112.14%
816,571 $196 Million
Q3 2021

Nov 09, 2021

BUY
$282.99 - $369.05 $16 Million - $20.9 Million
56,681 Added 17.27%
384,914 $109 Million
Q2 2021

Aug 13, 2021

BUY
$259.0 - $414.71 $8.52 Million - $13.6 Million
32,878 Added 11.13%
328,233 $114 Million
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $49.9 Million - $58.4 Million
-205,329 Reduced 41.01%
295,355 $82.6 Million
Q4 2020

Feb 11, 2021

BUY
$236.26 - $355.63 $19.2 Million - $29 Million
81,422 Added 19.42%
500,684 $123 Million
Q3 2020

Nov 12, 2020

BUY
$264.77 - $305.71 $10.7 Million - $12.3 Million
40,253 Added 10.62%
419,262 $119 Million
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $5.18 Million - $6.86 Million
-20,026 Reduced 5.02%
379,009 $101 Million
Q1 2020

May 13, 2020

SELL
$268.85 - $341.04 $71.4 Million - $90.5 Million
-265,491 Reduced 39.95%
399,035 $126 Million
Q4 2019

Feb 10, 2020

BUY
$220.06 - $304.07 $30.7 Million - $42.5 Million
139,725 Added 26.62%
664,526 $197 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $3.17 Million - $3.55 Million
14,557 Added 2.85%
524,801 $122 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $26.2 Million - $28.8 Million
119,272 Added 30.51%
510,244 $119 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $698,456 - $1.09 Million
-3,223 Reduced 0.82%
390,972 $92.4 Million
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $15.1 Million - $19.2 Million
54,310 Added 15.98%
394,195 $119 Million
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $3.98 Million - $5.2 Million
-13,556 Reduced 3.84%
339,885 $120 Million
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $30.3 Million - $36.2 Million
-117,833 Reduced 25.0%
353,441 $103 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $42 Million - $59.3 Million
161,284 Added 52.03%
471,274 $129 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $48 Million - $53.8 Million
156,148 Added 101.5%
309,990 $98.8 Million
Q3 2017

Nov 14, 2017

BUY
$281.15 - $329.69 $43.3 Million - $50.7 Million
153,842
153,842 $48.2 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.